Parkinson’s Disease

Neuro startup Vanqua Bio emerges with $85M and a first focus on Parkinson’s

Vanqua Bio aims to treat rare form of Parkinson’s disease by boosting activity of an enzyme that is deficient in patients who have a particular genetic mutation. With $85 million in Series B financing, the biotech startup, which is based on Northwestern University research, aims to reach human testing within two years.

Mayo Clinic, Google develop AI algorithm to enhance electrical brain stimulation

The algorithm maps interactions between different areas of the brain, which can help guide the placement of electrodes for stimulating devices to treat brain diseases, like epilepsy, and movement disorders.

The FDA’s Culture: Should Safety Dominate All Practices?

By STEVEN ZECOLA An organization’s culture is an internal set of shared values, attitudes and practices. The cohesiveness of the organizational culture will affect whether the entity will meet its vision, purpose, and goals. One type of organizational culture is hierarchical in nature.   Unlike a risk-taking culture, this structure features policy, process and precision. It is …

The FDA’s Culture: Should Safety Dominate All Practices? Read More »

AC Immune picks up Phase 2-ready drug for Parkinson’s in $58M deal with Affiris

AC Immune is bolstering the Parkinson’s disease portion of its drug pipeline with a deal to acquire a therapeutic vaccine that Affiris is developing for the disorder. Switzerland-based AC Immune plans to advance its new asset to Phase 2 testing.

Boost for AZ as Ultomiris gets CHMP nod for expanded label

Fresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion of the label of Ultomiris, one of the main assets behind the $39 billion merger. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has backed the approval of Ultomiris (ravulizumab) for children and adolescents with …

Boost for AZ as Ultomiris gets CHMP nod for expanded label Read More »

FDA gives speedy review to Bayer’s Parkinson’s stem cell therapy

Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson’s disease which is currently in early-stage clinical testing. The FDA designation allows for benefits such as more frequent meetings and communication with the regulator during clinical development, and a truncated six-month review time. Those …

FDA gives speedy review to Bayer’s Parkinson’s stem cell therapy Read More »

Ipsen tries again in Parkinson’s disease with $363m IRLAB deal

French drugmaker Ipsen has made another foray into the Parkinson’s disease category, licensing rights to an oral dopamine D3 receptor antagonist from Sweden’s IRLAB for $28 million upfront.  The deal gives Ipsen worldwide rights to the mid-stage drug – called mesdopetam – and puts the company on the hook for another $335 million in development, …

Ipsen tries again in Parkinson’s disease with $363m IRLAB deal Read More »

The Case to Realign Parkinson’s Disease Research

By STEVEN ZECOLA If asked, the leaders of the research organizations working on Parkinson’s disease would say that they have made tremendous progress and are optimistic on finding a cure for the disease.  In truth, this viewpoint understates the magnitude of the challenge and results in insufficient resources being devoted to PD. Given the size …

The Case to Realign Parkinson’s Disease Research Read More »

GSK adds neuro prospects, paying $700M to share R&D of Alector’s two lead drugs

GlaxoSmithKline is paying Alector $700 million up front to share in the development of the biotech’s two lead drugs, which offer potentially broad application in treating neurological disorders. Alector’s approach addresses the role immune cell dysfunction plays in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.

AbbVie Collaborates with Caraway to Develop TMEM175 for Parkinson’s Disease and Other Related Disorders

Shots: Caraway to receive ~$267M including $17M up front in cash and remaining as option payment & milestones and is eligible for additional regulatory and commercial milestones along with royalties & gets the option to take part in product development in exchange for higher royalty rates Post pre-clinical research and development activities, AbbVie has an …

AbbVie Collaborates with Caraway to Develop TMEM175 for Parkinson’s Disease and Other Related Disorders Read More »

Bayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinic

Bayer subsidiary BlueRock Therapeutics has dosed the first Parkinson’s disease patient in a phase 1 trial of its cell-based therapy DA01, which aims to replenish the neurons lost in people with the neurodegenerative disorder. At the same time, the German group’s Asklepios BioPharma (AskBio) unit has started recruiting patients for a phase 1b trial of …

Bayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinic Read More »

Cambridge Sleep Sciences’ device is trialled in Parkinson’s

Sleep disturbances are a common feature for people with Parkinson’s disease, and a device developed to help people with insomnia is now being trialled to see if it can improve their sleep quality.  The SleepHub device – developed by Barkby group company Cambridge Sleep Sciences – is on the face of it a box and …

Cambridge Sleep Sciences’ device is trialled in Parkinson’s Read More »

AI drug discovery firm Valence joins Parkinson’s disease push

Canada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat the involuntary movement complications that can accompany treatments for Parkinson’s disease.  The go-to treatment for the five million people worldwide with Parkinson’s is levodopa, which replaces the activity of the dopamine neurotransmitter dopamine that gets depleted by …

AI drug discovery firm Valence joins Parkinson’s disease push Read More »

Gene and Cell Therapies in CNS Disorders: Miracle Cure? Opportunities Galore!

CNS disorders are a wide-ranging set of disorders in which the brain loses its normal functioning, limiting everyday ability to function. These may arise from various reasons-some are inherited, some result from damage, and some from infections. It contributes to the highest disability-adjusted life years. The current treatment options are minimal. Most of the disorders …

Gene and Cell Therapies in CNS Disorders: Miracle Cure? Opportunities Galore! Read More »

Patients as Partners Europe: Are we doing patient centricity all wrong?

To be truly patient centric, do we need to turn the current model on its head and work within a more free-thinking, free-speaking framework? Amanda Barrell reports from Patients as Partners Europe. Despite huge progress over the last decade, patient involvement in research is still largely in the hands of the pharmaceutical companies. That is …

Patients as Partners Europe: Are we doing patient centricity all wrong? Read More »

Parkinson’s Disease: How close are we to a cure?

Neurological disorders are the leading source of disability globally, and Parkinson’s is the fastest-growing neurological condition. It could be due to several factors ranging from an increase in geriatric population, longevity, improved diagnostics methodologies, a better understanding of the disease to the specific use of some pesticides, and industrialization. The number of individuals with Parkinson’s …

Parkinson’s Disease: How close are we to a cure? Read More »

Lilly pays up to $1.04bn for neurology gene therapy biotech Prevail

Eli Lilly has acquired Prevail, a biotech focusing on gene therapies for neurodegenerative diseases including Parkinson’s, in a deal potentially worth more than $1 billion. The big US pharma is to pay up to $1.04 billion to buy Prevail, paying $22.5 per share up front plus a $4 contingent value right (CVR) to sweeten the …

Lilly pays up to $1.04bn for neurology gene therapy biotech Prevail Read More »

Advancements in Neuromodulation

According to the International Neuromodulation Society, neuromodulation is “the alteration—or modulation—of nerve activity by delivering electrical or pharmaceutical agents directly to a target area“. The neuromodulation space is witnessing one of the fastest-growing medical device markets in the healthcare industry. Several big industry players such as Abbott, Boston Scientific, and Medtronic have developed life-changing Neuromodulation …

Advancements in Neuromodulation Read More »

Eisai forges CNS alliance with UK’s Wren Therapeutics

Japanese drugmaker Eisai has teamed up with UK biotech Wren Therapeutics on an R&D programme seeking drugs for neurodegenerative disorders. The two companies will focus their efforts on alpha-synuclein, a pathway that has been implicated in disorders such as dementia with Lewy bodies (DLB) and Parkinson’s disease (PD). DLB and PD are both so-called synucleinopathies, …

Eisai forges CNS alliance with UK’s Wren Therapeutics Read More »

Sublingual Apomorphine (Kynmobi) for Parkinson’s Disease

Date:  October 19, 2020 Issue #:  1609 Summary:  The FDA has approved a sublingual fi lm formulation of the nonergot dopamine agonist apomorphine (Kynmobi – Sunovion) for acute, intermittent treatment of “off” episodes in patients with Parkinson’s disease (PD). A subcutaneous formulation of apomorphine (Apokyn) has been available for years for the same indication in …

Sublingual Apomorphine (Kynmobi) for Parkinson’s Disease Read More »

Axovant pushes on with Parkinson’s gene therapy, despite investor cynicism

Axovant has said it plans to continue developing its Parkinson’s Disease gene therapy after reporting supportive data from a small cohort of patients from a phase 2 trial. However shares in Axovant were down sharply after the announcement because of market sentiment that the New York biotech had been selective with the data it had …

Axovant pushes on with Parkinson’s gene therapy, despite investor cynicism Read More »

STADA Expands its Specialty Footprint with the Acquisition of Lobsor Pharmaceuticals

Shots:   STADA acquires Lobsar and its innovative therapy to foster its footprints in specialty pharmaceuticals. The acquisition complements STADA’s portfolio and expertise in the treatment of late-stage Parkinson’s disease With the acquisition, STADA gain rights to a triple fixed combination (levodopa/carbidopa/ entacapone) delivered via modern pump technology, already launched in Nordic countries Levodopa, carbidopa and …

STADA Expands its Specialty Footprint with the Acquisition of Lobsor Pharmaceuticals Read More »

Biogen Signs an Agreement with Denali on LRRK2 Program for Parkinson’s Disease Worth ~$2.125B

Shots: Denali to receive $560M up front, $465M as equity investment at a price of $34.94/ share, representing 11.2% of Denali’s Pro-forma outstanding stock along with $1.125B as milestones. The two companies will codevelop Denali’s LRRK2 inhibitor for PD and co-commercialize it in the US and China while Biogen has the right to commercialize the …

Biogen Signs an Agreement with Denali on LRRK2 Program for Parkinson’s Disease Worth ~$2.125B Read More »

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant to Manufacture and Supply AXO-Lenti-PD for Parkinson’s Disease

Shots: Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD (formerly OXB-102) to treat mod. to sev. PD based on Oxford’s LentiVector platform Axovant is conducting a P-II SUNRISE-PD trial with AXO-Lenti-PD while the dosing of all patients in the second cohort is completed with 6mos. …

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant to Manufacture and Supply AXO-Lenti-PD for Parkinson’s Disease Read More »